mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)

Shernan G. Holtan, Luis F. Porrata, Joseph P. Colgan, Clive S. Zent, Thomas M. Habermann, Svetomir N. Markovic

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)'. Together they form a unique fingerprint.